Do not get in RAGE in cardiogenic shock: It is detrimental!

Critical Care Medicine

Volumn 40, Issue 5, 2012, Pages 1669-1670

  Werdan, Karl ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cardiogenic shock; IABP SHOCK trial; IL 6; myocardial infarction; receptor for advanced glycation end products (RAGE); soluble receptor for advanced glycation end products (sRAGE)

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CREATINE; INTERLEUKIN 6; PROTEIN; RAGE PROTEIN; UNCLASSIFIED DRUG;

APACHE; AREA UNDER THE CURVE; CARDIOGENIC SHOCK; CREATININE CLEARANCE; EDITORIAL; HEART INDEX; HEART INFARCTION; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE;

FEMALE; HUMANS; MALE; RECEPTORS, IMMUNOLOGIC; SHOCK, CARDIOGENIC;

EID: 84860257894     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182474c20     Document Type: Editorial

References (15)

1. Hochman JS, Ohman EM (Eds): Cardiogenic Shock. The AHA Clinical Series. Hoboken, NJ, Wiley-Blackwell, 2009
2. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341:625-634
3. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511-2515
4. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107:2998-3002
5. Kohsaka S, Menon V, Lowe AM, et al: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165:1643-1650
6. Geppert A, Steiner A, Zorn G, et al: Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002; 30:1987-1994
7. Prondzinsky R, Lemm H, Swyter M, et al: Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38:152-160
8. Selejan S-R, Poss J, Hewera L, et al: Role of receptor for advanced glycation end products in cardiogenic shock. Crit Care Med 2012; 40:1513-1522
9. Katz JN, Stebbins AL, Alexander JH, et al: Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 2009; 158:680-687
10. Cotter G, Williams SG, Vered Z, et al: Role of cardiac power in heart failure. Curr Opin Cardiol 2003; 18:215-222
11. Fincke R, Hochman JS, Lowe AM, et al: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44:340-348
12. Schuster HP, Schuster FP, Ritschel P, et al: The ability of the Simplified Acute Physiology Score (SAPS II) to predict outcome in coronary care patients. Intensive Care Med 1997; 23:1056-1061
13. Fuhrmann JT, Schmeisser A, Schulze MR, et al: Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36:2257-2266
14. Cotter G, Kaluski E, Milo O, et al: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study. Eur Heart J 2003; 24:1287-1295
15. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al: Effects of tilarginine in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. JAMA 2007; 297:1657-1666